These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

468 related articles for article (PubMed ID: 33785741)

  • 1. Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer.
    Baca SC; Takeda DY; Seo JH; Hwang J; Ku SY; Arafeh R; Arnoff T; Agarwal S; Bell C; O'Connor E; Qiu X; Alaiwi SA; Corona RI; Fonseca MAS; Giambartolomei C; Cejas P; Lim K; He M; Sheahan A; Nassar A; Berchuck JE; Brown L; Nguyen HM; Coleman IM; Kaipainen A; De Sarkar N; Nelson PS; Morrissey C; Korthauer K; Pomerantz MM; Ellis L; Pasaniuc B; Lawrenson K; Kelly K; Zoubeidi A; Hahn WC; Beltran H; Long HW; Brown M; Corey E; Freedman ML
    Nat Commun; 2021 Mar; 12(1):1979. PubMed ID: 33785741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FOXA1 inhibits prostate cancer neuroendocrine differentiation.
    Kim J; Jin H; Zhao JC; Yang YA; Li Y; Yang X; Dong X; Yu J
    Oncogene; 2017 Jul; 36(28):4072-4080. PubMed ID: 28319070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Post-transcriptional Gene Regulation by MicroRNA-194 Promotes Neuroendocrine Transdifferentiation in Prostate Cancer.
    Fernandes RC; Toubia J; Townley S; Hanson AR; Dredge BK; Pillman KA; Bert AG; Winter JM; Iggo R; Das R; Obinata D; ; Sandhu S; Risbridger GP; Taylor RA; Lawrence MG; Butler LM; Zoubeidi A; Gregory PA; Tilley WD; Hickey TE; Goodall GJ; Selth LA
    Cell Rep; 2021 Jan; 34(1):108585. PubMed ID: 33406413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ONECUT2 acts as a lineage plasticity driver in adenocarcinoma as well as neuroendocrine variants of prostate cancer.
    Qian C; Yang Q; Rotinen M; Huang R; Kim H; Gallent B; Yan Y; Cadaneanu RM; Zhang B; Kaochar S; Freedland SJ; Posadas EM; Ellis L; Di Vizio D; Morrissey C; Nelson PS; Brady L; Murali R; Campbell MJ; Yang W; Knudsen BS; Mostaghel EA; Ye H; Garraway IP; You S; Freeman MR
    Nucleic Acids Res; 2024 Jul; 52(13):7740-7760. PubMed ID: 38932701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Androgen receptor-independent function of FoxA1 in prostate cancer metastasis.
    Jin HJ; Zhao JC; Ogden I; Bergan RC; Yu J
    Cancer Res; 2013 Jun; 73(12):3725-36. PubMed ID: 23539448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesis.
    Pomerantz MM; Li F; Takeda DY; Lenci R; Chonkar A; Chabot M; Cejas P; Vazquez F; Cook J; Shivdasani RA; Bowden M; Lis R; Hahn WC; Kantoff PW; Brown M; Loda M; Long HW; Freedman ML
    Nat Genet; 2015 Nov; 47(11):1346-51. PubMed ID: 26457646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LIN28B promotes the development of neuroendocrine prostate cancer.
    Lovnicki J; Gan Y; Feng T; Li Y; Xie N; Ho CH; Lee AR; Chen X; Nappi L; Han B; Fazli L; Huang J; Gleave ME; Dong X
    J Clin Invest; 2020 Oct; 130(10):5338-5348. PubMed ID: 32634132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SRRM4 Drives Neuroendocrine Transdifferentiation of Prostate Adenocarcinoma Under Androgen Receptor Pathway Inhibition.
    Li Y; Donmez N; Sahinalp C; Xie N; Wang Y; Xue H; Mo F; Beltran H; Gleave M; Wang Y; Collins C; Dong X
    Eur Urol; 2017 Jan; 71(1):68-78. PubMed ID: 27180064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pioneer of prostate cancer: past, present and the future of FOXA1.
    Teng M; Zhou S; Cai C; Lupien M; He HH
    Protein Cell; 2021 Jan; 12(1):29-38. PubMed ID: 32946061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fascin-1 expression is associated with neuroendocrine prostate cancer and directly suppressed by androgen receptor.
    Turpin A; Delliaux C; Parent P; Chevalier H; Escudero-Iriarte C; Bonardi F; Vanpouille N; Flourens A; Querol J; Carnot A; Leroy X; Herranz N; Lanel T; Villers A; Olivier J; Touzet H; de Launoit Y; Tian TV; Duterque-Coquillaud M
    Br J Cancer; 2023 Dec; 129(12):1903-1914. PubMed ID: 37875732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FOXA1 modulates EAF2 regulation of AR transcriptional activity, cell proliferation, and migration in prostate cancer cells.
    Guo W; Keener AL; Jing Y; Cai L; Ai J; Zhang J; Fisher AL; Fu G; Wang Z
    Prostate; 2015 Jun; 75(9):976-87. PubMed ID: 25808853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Temporal evolution of cellular heterogeneity during the progression to advanced AR-negative prostate cancer.
    Brady NJ; Bagadion AM; Singh R; Conteduca V; Van Emmenis L; Arceci E; Pakula H; Carelli R; Khani F; Bakht M; Sigouros M; Bareja R; Sboner A; Elemento O; Tagawa S; Nanus DM; Loda M; Beltran H; Robinson B; Rickman DS
    Nat Commun; 2021 Jun; 12(1):3372. PubMed ID: 34099734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RNA Splicing of the BHC80 Gene Contributes to Neuroendocrine Prostate Cancer Progression.
    Li Y; Xie N; Chen R; Lee AR; Lovnicki J; Morrison EA; Fazli L; Zhang Q; Musselman CA; Wang Y; Huang J; Gleave ME; Collins C; Dong X
    Eur Urol; 2019 Aug; 76(2):157-166. PubMed ID: 30910347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer.
    Singh N; Ramnarine VR; Song JH; Pandey R; Padi SKR; Nouri M; Olive V; Kobelev M; Okumura K; McCarthy D; Hanna MM; Mukherjee P; Sun B; Lee BR; Parker JB; Chakravarti D; Warfel NA; Zhou M; Bearss JJ; Gibb EA; Alshalalfa M; Karnes RJ; Small EJ; Aggarwal R; Feng F; Wang Y; Buttyan R; Zoubeidi A; Rubin M; Gleave M; Slack FJ; Davicioni E; Beltran H; Collins C; Kraft AS
    Nat Commun; 2021 Dec; 12(1):7349. PubMed ID: 34934057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate cancer reactivates developmental epigenomic programs during metastatic progression.
    Pomerantz MM; Qiu X; Zhu Y; Takeda DY; Pan W; Baca SC; Gusev A; Korthauer KD; Severson TM; Ha G; Viswanathan SR; Seo JH; Nguyen HM; Zhang B; Pasaniuc B; Giambartolomei C; Alaiwi SA; Bell CA; O'Connor EP; Chabot MS; Stillman DR; Lis R; Font-Tello A; Li L; Cejas P; Bergman AM; Sanders J; van der Poel HG; Gayther SA; Lawrenson K; Fonseca MAS; Reddy J; Corona RI; Martovetsky G; Egan B; Choueiri T; Ellis L; Garraway IP; Lee GM; Corey E; Long HW; Zwart W; Freedman ML
    Nat Genet; 2020 Aug; 52(8):790-799. PubMed ID: 32690948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Crosstalk between androgen and pro-inflammatory signaling remodels androgen receptor and NF-κB cistrome to reprogram the prostate cancer cell transcriptome.
    Malinen M; Niskanen EA; Kaikkonen MU; Palvimo JJ
    Nucleic Acids Res; 2017 Jan; 45(2):619-630. PubMed ID: 27672034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cooperativity and equilibrium with FOXA1 define the androgen receptor transcriptional program.
    Jin HJ; Zhao JC; Wu L; Kim J; Yu J
    Nat Commun; 2014 May; 5():3972. PubMed ID: 24875621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Darolutamide antagonizes androgen signaling by blocking enhancer and super-enhancer activation.
    Baumgart SJ; Nevedomskaya E; Lesche R; Newman R; Mumberg D; Haendler B
    Mol Oncol; 2020 Sep; 14(9):2022-2039. PubMed ID: 32333502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of Novel Diagnosis Biomarkers for Therapy-Related Neuroendocrine Prostate Cancer.
    Zhang C; Qian J; Wu Y; Zhu Z; Yu W; Gong Y; Li X; He Z; Zhou L
    Pathol Oncol Res; 2021; 27():1609968. PubMed ID: 34646089
    [No Abstract]   [Full Text] [Related]  

  • 20. Molecular events in neuroendocrine prostate cancer development.
    Wang Y; Wang Y; Ci X; Choi SYC; Crea F; Lin D; Wang Y
    Nat Rev Urol; 2021 Oct; 18(10):581-596. PubMed ID: 34290447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.